TrialJournal of the National Comprehensive Cancer Network : JNCCN2024

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.

Saranya Chumsri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.